Agenus Inc. (AGEN)

Agenus's stock has been impacted by several events, including a plunge after the FDA discouraged accelerated approval for its BOT/BAL combination therapy, liquidity issues and the indefinite delay of a BLA filing, securing a $22 million mortgage, reporting Q4 and full-year 2024 results, reporting Q1 2025 financial results, announcing a strategic collaboration with Zydus Lifesciences, achieving a 42% two-year survival rate with BOT/BAL in refractory MSS mCRC and reaching an agreement with the FDA on the design of the global BATTMAN Phase 3 trial, reporting Q2 2025 financial results, participating in the H.C. Wainwright 27th Annual Global Investment Conference, holding an October 2025 Stakeholder Briefing Webcast, reporting Q3 2025 earnings, hosting an End of Year 2025 Stakeholder Briefing Webcast, reporting deep and durable responses with the BOT/BAL combination in highly refractory ovarian cancer, and France expanding national Accelerated Access Cohort (AAC) access for Agenus's Botensilimab + Balstilimab for ovarian cancer and soft-tissue sarcomas. As of January 8, 2026, the stock price was $3.76, representing a 10.59% increase from $3.40 on January 8, 2025.

Agenus Inc.'s revenue is primarily derived from strategic partnerships, licensing deals, and royalties, rather than commercial product sales, so there is no discernible pattern of demand seasonality. The demand for its investigational therapies is driven by clinical trial progress, regulatory milestones, and the unmet medical needs in oncology, which are not typically subject to seasonal fluctuations.

Agenus, Inc. is a clinical-stage immuno-oncology company focused on discovering, developing, and manufacturing therapies that harness the body's immune system to combat cancer and infectious diseases. The company's major product pipeline candidates include Botensilimab, Balstilimab, Prophage vaccines, QS-21 Stimulon® adjuvant, Invariant Natural Killer T (iNKT) cell therapies and other Checkpoint Modulators.

Agenus Inc. is headquartered in Lexington, Massachusetts, United States, and maintains a global clinical operations footprint with subsidiaries and facilities in Belgium, the United Kingdom, Ireland, and Switzerland. In the United States, beyond its headquarters, Agenus has facilities in California, specifically Berkeley and Vacaville.

Agenus's brand reputation has been shaped by clinical advancements and regulatory challenges. Positive developments, such as the survival rate of BOT/BAL in refractory MSS mCRC and the FDA's agreement on the Phase 3 trial design, have bolstered its scientific credibility. The expansion of national access for BOT/BAL in France and the strategic collaboration with Zydus Lifesciences enhance its reputation. However, the FDA's discouragement of accelerated approval for BOT/BAL and financial reports indicating reduced cash balances present challenges to its reputation.

Agenus Inc.'s ownership structure includes a significant presence of institutional investors, alongside individual and retail shareholders. As of April 2025, institutional investors held approximately 35.41% of Agenus shares, and this figure was around 30.11% in early November 2025. Insider ownership stood at 0.74% in April 2025 and 1.71% in July 2025. Major institutional owners include The Vanguard Group, Inc., BlackRock, Inc., and Geode Capital Management, Llc. Key individual owners include Garo H. Armen and Incyte Corp.